What is irRECIST?

irRECIST (Immune-related Response Evaluation Criteria In Solid Tumors) is a set of published rules that provide better assessment of the effect of immunotherapeutic agents.

Since its publication, irRECIST has been validated by the team at EMD Merck Serono in >1800 patients in various solid tumor indications, demonstrating that select patients do have clinical benefit including favorable association with Overall Survival from continued treatment after a RECIST PD.

https://pubmed.ncbi.nlm.nih.gov/35228264/